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Abstract 
EVALUATING TARGETED AND IMMUNOMODULATORY THERAPIES FOR 
MELANOMA IN A GENETICALLY ENGINEERED MOUSE MELANOMA MODEL. 
Billy J. Lockhart, Marcus Bosenberg. Department of Dermatology, Yale 
University, School of Medicine, New Haven, CT. 
Melanoma therapy has changed rapidly due to the emergence of new therapies: 
MAPK-pathway targeted drugs and immunomodulatory agents. Given the relative 
success of these new individual drugs, this work set out to evaluate and develop 
effective melanoma treatments using combination therapies in a preclinical 
mouse melanoma models. Therapies tested include BRAF kinase inhibition in 
combination with: immune checkpoint inhibitors anti-CTLA4, anti-PDL1, and with 
the topical TLR7/8 agonist imiquimod. Drugs efficacies were tested in established 
melanomas in a conditional inducible mouse melanoma model based on 
activation of Braf and beta catenin and loss of Pten.  BRAF inhibition in 
combination with anti-CTLA-4/anti-PD-L1 was not more effective than BRAF 
inhibition alone in retarding tumor growth or prolonging survival in these studies. 
Treatment with imiquimod significantly retarded tumor growth and increased 
survival. Imiquimod-treated tumors show increased macrophage infiltration, but 
not increased intratumoral T lymphocytes. Further work remains to identify 
effective, synergistic drug combinations in preclinical models.   
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Introduction 
Melanoma, a cancer that arises from melanocytes, among the skin cancer 
possesses the highest morbidity and mortality. In the United States, it is 
estimated that 76,690 cases of melanoma and 9,480 deaths due to melanoma 
occurred in 2013 (1). Melanoma incidence predominates in countries with 
conjunction of fair-skinned ethnic populations and high UV light exposure, and 
global incidence of melanoma continues to rise (2): 132,00 new cases are 
diagnosed world-wide and an estimated 48,000 persons die from advanced 
melanoma across the globe each year (3) (4). From 1950 to 2000, a national 
cancer database documented increases of 619 percent in annual diagnoses of 
cutaneous melanoma and 165 percent in annual mortality from 1950 to 2000 (5).  
At the initial diagnosis of a primary melanoma, the depth of the primary lesion is 
used to predict patient survival. For instance, survival at 10 years for a melanoma 
less than 1.00 mm in depth is greater than 90% (6). However, once melanoma 
has metastasized, the standard of care treatments offer little in the way of long 
term benefit:  a 2009 report estimated one-year survival based on location of 
melanoma spread as high as 62% and as low as 33% (6). Thus, high mortality 
rates associated with unresectable or metastatic melanoma persists, and given 
the high mortality rates and the relatively young age at which disease often 
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occurs, melanoma skin cancer was the second leading causes of lost productive 
years among cancers (5). 
  
Current therapeutic landscape 
Local Excision of Primary: 
If melanoma is diagnosed early, standard treatment involves wide local excision 
+/- sentinel lymph node biopsy based on thickness, ulceration status and a 
melanoma specific depth level known as the Clark level (5). High dose 
administration of Interferon alfa-2b, a type1 interferon that activates both innate 
and adaptive immune responses, has been studied as an adjuvant therapy in 
patients who have high-risk prognostic factors upon local melanoma excision. 
Multiple studies documented improvement in relapse-free survival, and two 
studies showed significantly improved overall survival among patients receiving 
high-dose interferon alfa-2b, and these reports lead to FDA approval of this 
treatment for patients whose initial primary lesions are greater than 4 mm in 
thickness (i.e., stage IIB or IIC) or for melanoma that involves a regional lymph 
node(s) excised during sentinel lymph node biopsy (i.e., stage III) (5). However, 
upon longer follow-up of these clinical trials, a significant long-term overall 
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Targeted Cancer Therapies 
Note again that a relatively small tumor of a depth slightly larger than 1 mm has a 
high metastatic potential. It is this metastatic disease that causes nearly all 
melanoma-associated mortality. Until recently, no therapy for advanced 
melanoma resulted in a significant increase in median overall survival. 
Dacarbazine, an alkylating agent first approved in 1975, is associated with 
overall survival of 5.6 to 7.8 months, and had been the mainstay of 
chemotherapy treatment until recently (8) (9). However, recent translational 
research in the field of melanoma therapeutics has yielded a string of new FDA 
approvals and large center clinical trials of several new agents. 
 
Building on the success of rational drug design in other cancers, a new class of 
protein inhibitors that target key signaling cascades essential to melanoma 
growth has emerged. The BRAF gene encodes an intracellular serine/threonine 
kinase in the Raf family, B-raf, which has a primary role in mitogen signaling 
pathways. The BRAF gene is mutated in approximately 50% (40-60%) of human 
melanomas, and these mutations are predominately of the activating substitution 
type, the majority characterized as BRAFV600E(~90%)  (10). This mutation results 
in constitutive downstream activation of the mitogen-activated protein kinase 
(MAPK) pathway, contributing to melanoma development and growth. 
Vemurafenib was the first of the new class of BRAF inhibitor approved in 2011 for 
advanced melanoma with BRAFV600 mutations. The drug is able to induce potent, 
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specific inhibition of mutated BRAF protein, providing for significant, often 
dramatic, responses in treated patients and significant increases in progression 
free survival and overall survival. Dabrafenib is a newer BRAF inhibitor and has 
also been shown to improve response rates, progression-free and overall 
survival, significantly compared to chemotherapy (11, 12). Still others are in 
development. However, in the vast majority of patients, the initial response to this 
targeted inhibition is followed by the successive development of a total BRAF 
inhibitor resistance; it appears regularly in approximately six to nine months (12, 
13). Some evidence suggests that that reactivation of the MAPK pathway may 
play a key role in the overcoming of BRAF inhibition in patients treated with these 
drugs (12). 
 
Not surprisingly, another new class of targeted protein inhibitors target MEK, a 
kinase that is downstream of Raf kinases in the MAPK pathway. Trametinib, a 
MEK inhibitor, has recently been FDA approved as a monotherapy in melanoma, 
and was associated with a survival advantage as compared with chemotherapy 
(14). In results that bear similarity to those of the BRAF inhibitors class of agents, 
objective response rates are initially high with MEK inhibitors, but the response is 
not durable, and resistance to therapy emerges within 6-18 months in most 
cases (14).  
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Two phase 3 trials published in 2014 tested whether the combination of these 
two classes--the MEK and BRAF inhibitors, i.e. dabrafenib or vemurafenib plus 
trametinib--would improve outcomes and response duration compared with 
BRAF inhibition, vemurafenib or dabrafenib, monotherapy (12, 15). Robert et al. 
described evidence that the combination of dabrafenib plus trametinib 
significantly improved overall survival in previously untreated patients with BRAF 
V600E or V600K mutation positive metastatic melanoma without increased 
overall toxicity: the median progression free survival was 11.4 months in the 
combination vs. 7.3 in vemurafenib only group (15). The authors concluded that 
by combining trametinib with dabrafenib “results in a significant delay in the 
emergence of resistant, and longer progression-free survival, with a longer 
median progression-free survival than with dabrafenib alone… and is superior to 
vemurafenib monotherapy with regard to all efficacy end points, including overall 
survival, with no additional overall toxicity (15).” Long et al describe a similar trial 
comparing the same combination to dabrafenib plus placebo: the median 
progression-free survival 9.9 vs 8.8 months respectively, and the two groups had 
nearly identical objective response rates to the Robert et al study (12, 15). While 
the data supported the authors’ claim that the combination has better response 
rates than anti-BRAF monotherapy, ~40% of patients w/BRAFV600 mutation did 
not benefit from the combination and the median improvement in progression 
free survival was only four months versus vemurafenib monotherapy and only 
one month versus dabrafenib monotherapy. This evidence also demonstrates 
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that resistance to BRAF/MEK inhibition occurs in the nearly all cases, indicating 
that this approach will not cure a significant proportion of melanoma patients. 
 
Immune therapies 
Small molecule inhibitors targeted to driver mutations or essential pro-growth 
signaling pathways are one branch of the new therapies to emerge in the clinical 
arsenal against advanced melanoma in the last four years. The other branch can 
be broadly classified as immune-based therapies that harness the immune 
response to clear the aberrant cells. This branch is comprised of a cell-based 
therapy, monoclonal antibody-based immunomodulatory therapies, and Toll Like 
Receptor (TLR) agonists.  
TIL-based therapy 
The first, Adoptive T-cell therapy (ACT), consist of the isolation and then adoptive 
transfer of the autologous tumor-infiltrating lymphocytes (TILs) after significant 
ex-vivo expansion using various treated culture media. Long-term follow-up of 
patients who have been treated with tumor-infiltrating lymphocytes (TILs) for 
metastatic melanoma has demonstrated that a significant portion of those treated 
with this cell-based therapy experienced complete, durable tumor regression 
(16). A recent review cited a growing body of evidence that mutated gene 
products may act as the primary immunological targets of TILs that have been 
extracted and from melanomas and re-administered (16). Several recent clinical 
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trials studying TIL administration have taken place or are underway. One resulted 
in objective clinical responses in about 56% of the patients, and importantly with 
40% of those responders having complete response to the therapy (16, 17). The 
authors reported that 95% of the complete responders were long-lasting “i.e. 
ongoing after 64– 109 months of follow-up (16, 17).” Similar results have been 
achieved at other centers across the globe (16, 18, 19). ACT of TILs is therefore 
a life-saving therapy for those patients who respond to therapy, many of which 
have been purportedly cured. However, ~40-45% of patients do not respond, and 
the process of T cell maturation is time and labor intensive. In addition, a only a 
subset of metastatic melanoma patients can complete ACT, as many patients 
may not have a tumor suitable for extraction of TILS or the TILS do not grow 
adequately. As research centers continue to improve TIL treatments for 
melanoma, they will also test this platform in other types of cancer. 
Immunomodulatory Therapeutic Antibodies 
New advances in immunomodulatory therapeutic antibodies continue to redefine 
the landscape of melanoma therapy. Ipilimumab was the first in its class of 
immunomodulatory antibodies to be studied, and the first to show a survival 
benefit in advanced melanoma; it was first to be approved by the FDA in 2010. 
Ipilimumab is a monoclonal antibody that blocks the cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4).  CTLA-4 is a protein receptor found on the 
surface of T cells that binds to CD80 or 86 on antigen presenting cells; thus 
CTLA-4 signaling competes with CD28 signaling, and leads to T Cell inhibition, 
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thereby acting as a potent checkpoint in the immune response. Blocking CTLA-4 
leads to enhancement of antitumor activity. Ipilimumab has been show to 
improve the rate of survival at 1 and at 2 years, when compared to a peptide 
vaccine control, among previously treated patients with metastatic melanoma as 
well as among previously untreated patients who also received dacarbazine (9, 
20). Furthermore, long-term follow up of three recent Ipilimumab treatment 
groups reported 5 year survival rates between 13-25% with one the group 
following one protocol reporting a 17% complete response rate (21). However, 
the immune checkpoint blockade is a double-edged sword: high grade auto-
immune side effects (immune-mediated enterocolitis, hepatitis, dermatitis, and 
endocrinopathies) occur in approximately 1-6% of patients and in some cases 
result in discontinuation of the therapy (22). Ipilimumab monotherapy 
demonstrated the promise of immunomodulatory antibody therapies in the 
treatment of melanoma, but also suggested that there was room improvement.   
Another pathway in the immune system has seen application as a cancer 
therapeutic: the programmed death 1 signaling cascade. Expressed 
predominantly by T cells, programmed death-1 (PD-1) is a co-receptor. PD-1 
binds to its ligands, PD-L1 or PD-L2, in a process essential to the physiologic 
regulation of the immune system by acting as a negative signal that regulates    
T-cell activation and proliferation. Thus, a major function of the PD-1 signaling 
pathway is the inhibition of self-reactive T cells activity, which serves to guard 
against autoimmune diseases (8). Removal of the PD-1 pathway can 
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consequently produce a failure of immune tolerance, which ultimately could lead 
to the development of pathogenic autoimmunity (23). Conversely, tumor cells 
have co-opted the PD-1 pathway to evade immune surveillance (24, 25). 
Therefore, PD-1 pathway has become an attractive disruption target in cancer 
therapy. Several agents targeted to this pathway have been the subjects of 
recent experimental study: nivolumab, pembrolizumab, and lambrolizumab will be 
briefly discussed herein.  
 
Pembrolizumab, is an anti-PD-1 antibody that was FDA approved on the basis of 
an objective response rate of ~ 25% among patients with advanced melanoma 
(26).  Lambrolizumab, an anti-PD-L1 is currently in Phase 3 trials after a 
successful phase 2 trial in 2013 that showed response rates ~35%, with a 
durable response in the majority of patients and an overall median progression-
free survival that was longer than 7 months (27).  
The third agent, nivolumab, was the subject of several recent reports. Nivolumab 
is a fully human antibody also directed at inhibition of the programmed death 1 
(PD-1). In ipilimumab-refractory melanoma, nivolumab had higher rate of 
objective response then chemotherapy with dacarbazine (32% vs 11%): the 
nivolumab treated group had a one-year survival rate of 72.9% compared with 
42.1% with dacarbazine. This stage 3 study compared these two drugs in 
previously untreated BRAF-negative advanced melanoma. The median 
progression free survival was 5.1 months vs 2.2 and an objective response was 
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documented in 40% vs 14% of patients in the nivolumab and dacarbazine groups 
respectively (8).  
Nivolumab was also used in a Phase 1 trial in combination with ipilimumab with 
both a concurrent therapy treatment arm and a sequenced treatment arm (28). 
Reporting using strict response criteria, the objective-response rate in the 
concurrent-regimen group was 40% (with the authors stating that any clinical 
activity was observed in 65% of patient), while the objective response rate in the 
sequenced treatment arm was 20% (28). Given the serious auto-immune based 
adverse effects with ipilimumab alone, it is perhaps not surprising that high-grade 
adverse events (3 or 4) were reported in 53% of the patients who received 
concurrent therapy vs 18% in the sequenced group (28).  Of note, at the highest 
dosages with an acceptable level of adverse events, 53% of patients had an 
objective response that consisted of significant tumor reduction of  > or =80% 
(28). The two-year survival of the combined therapy cohort was 80%, far greater 
than historical non-treatment controls (~25%). 
TIL and Immunomodulatory therapeutic antibodies that target immune 
checkpoints have been established as clinically effective and for some may 
represent long-term remission (and possibly cure) from disease progression: a 
triumph of modern medicine in the battle against cancer. A similar pattern to the 
previously described new therapeutic options is reflected in these results: a 
subset of patients has significant improvement, especially as compared to 
previous standard of care chemotherapy. But substantial ground remains to be 
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covered: TIL, anti-CTLA-4, and anti-PD-1 inhibitor studies reveal large 
proportions of patients who do not respond to therapy, and to date no predictive 
biomarkers have been identified and some patients lack the appropriate T cells in 
their tumors to be candidates for TIL therapy. Current opinion is that response 
biomarkers may someday help to predict candidates who would benefit from 
therapy, but to date no such markers have been validated, e.g. prognostic role of 
for instance PD-L1 status has yet to be determined(8). 
 
Toll-like receptor agonists 
Chemical agents that exhibit the ability to potently activate the innate immune 
response have been tested and used as therapeutics to treat skin cancers. 
Particular attention has been focused upon Toll-like receptor (TLR) agonists in 
the family of compounds known as the imidazoquinolines, e.g. imiquimod and 
resiquimod, which activate TLR 7 and TLR 8 and consequently, induction of 
nuclear factor-kappa B (NF-κB) (29). Imiquimod, an agonist thought to act 
predominately at TLR 7, was originally approved for the treatment of actinic 
keratosis and external genital warts. The compound has been found to be 
efficacious for basal cell and squamous cell cancers, and the FDA subsequently 
approved the use of topical imiquimod for the treatment of superficial basal cell 
carcinoma and squamous cell carcinoma (30). Further studies, mostly case 
reports, have evaluated the potential usefulness of imiquimod as a topical 
treatment for dermal metastases of melanoma that are not readily managed with 
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surgery (29). However many of these reports included other treatment modalities, 
complicating a pure assessment of the efficacy of imiquimod.  
For instance A phase I/II clinical trial suggests that imiquimod effectively treats 
many superficial dermal and subcutaneous melanoma metastases (31). In point 
of fact, Imiquimod was combined with intralesional Bacille Calmette-Guerin 
(ILBCG) in order to induce regressions of a portion of lesions in patients with 
mixed dermal and subcutaneous disease. The authors’ conclusion was that 
imiquimod alone could be used to effectively control dermal disease, but 
subcutaneous disease was better treated in combination with ILBCG(31).  
Alternative mechanisms of actions of imiquimod, besides a TLR-mediated 
response, have been proposed. Several groups have published evidence that 
argues for high dose imiquimod directly triggering apoptosis induction of 
apoptosis via Bcl-2 and caspase activation (32, 33). Another report looked at the 
vehicle for Aldara, the non-generic formulation of imiquimod, which is known to 
cause psoriatic-like inflammation when applied to murine epidermis (33). The 
authors of this study concluded that the vehicle for the drug, citing evidence 
pinpointing the isostearic acid component, was sufficient to induce inflammation 
in cultured keratinocytes and drawing into question whether or not imiquimod was 
solely responsible for all the therapeutic activity seen clinically (34). However, 
multiple vehicle-controlled, double blind studies have shown imiquimod efficacy 
in treating non-melanoma skin cancers (35, 36). 
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A mouse model of melanoma 
 
In order to further explore research questions about the genetic basis of 
melanoma development, the formation of melanoma metastasis, and potential 
therapeutics, a novel mouse model has been developed to investigate specific 
genetic mutations within the melanocytes of mice by the Bosenberg lab. The 
melanoma mouse model referred to has been constructed from a transgenic 
mouse line, which was previously engineered and characterized to express a Cre 
recombinase-estrogen receptor fusion protein controlled by a melanocyte-specific 
tyrosinase promoter (Tyr::CreERT) (37). The mouse model’s genetically 
engineered system allows for the inducible recombination of genes that contain 
lox sites flanking targeting the relevant DNA sequences of known melanoma 
genetic hits. Targeted DNA excision is reproducibly induced by the application of 
topical 4-hydroxytamoxifen (4-OHT), an estrogen agonist that binds to the 
estrogen receptor fusion protein in a spatially and temporally restricted manner 
(38). Following the demonstration of functionality of the Tyr::CreERT lines, lox 
knock-in and knockout lines of genes relevant to human melanoma were 
acquired including Braf, Pten and Bcat. 
 As previously described, the B-raf serine/threonine kinase is one of the 
most commonly mutated genes known in human melanoma, with about 50% of 
melanomas containing activating mutations of BRAF (usually Braf V600E) (39). 
Martin McMahon’s lab at UCSF produced a knock-in allele of activated BRAF 
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(BRAFCA) that is phenotypically wild type but after Cre-mediated recombination 
produces a constitutively active allele that contains the V600E point mutation 
found in human melanomas. This recombinant gene product retains a single 
intronic 34bp loxP site and the activating point mutation, but otherwise resembles 
the wild type chromosome exactly (38).  
 Studies of human melanoma tumor samples have revealed that the Pten 
tumor suppressor is markedly reduced in about 30% of advance melanoma, but 
the Pten gene itself is only mutated in a small proportion of melanomas (40).  The 
Bosenberg lab acquired a Pten allele which has lox sites inserted so as to flank 
exon 5 (38).  Subsequently, various mouse genotypes have been actively 
generated: previous work in the lab analyzed 4-OHT-treated mouse cohorts in 
which these targeted genes, Braf and Pten, as well as others key melanoma 
genes (Cdkn2a, p53, etc.) have be manipulated individually and in 
combination(s). When the inductions of genetic recombination are performed with 
a relatively high concentration of topical 4-OHT (50mg/ml in DMSO) applied to 
the mouse on days 3, 5, and 7 of life, the inductions result in a widespread 
recombination of lox-containing alleles specifically in melanocytes. Induction of 
constitutively active BrafV600E construct in melanocytes results in formation of 
small melanocytic nevi that stop growing after 3-4 weeks (37). Other genetic hits 
that have been experimentally examined in this system have not yielded a 
markedly abnormal melanocytic phenotype when altered individually. In contrast, 
when combinations of key genes have been recombined using 4OHT induction, 
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these combinations have yielded useful tumorigenic and metastatic phenotypes. 
Induction of BrafV600E combined with loss of Pten yields a dramatic melanoma 
phenotype (Braf/Pten tumor model). When recombination is induced in 
melanocytes throughout the mice within the first week of postnatal life, greater 
that 10,000 melanomas form without detectable latency. In contrast, when 
recombination is induced locally by application of 2 µL 4-OHT solution on flank 
skin after weaning, localized melanomas form and grow to 1 cm3 in 6-8 weeks 
without fail. This model allows for the production of melanoma driven by 
mutations relevant to human melanoma in an immune competent setting. 
 
In addition to these two key gene targets in the melanoma mouse model, the 
Bosenberg lab developed a novel genetically engineered model based on the 
Braf/Pten model with the addition of an inducible gene product that results in the 
stabilization of beta catenin (Ctnnb1loxex3 ), resulting in constitutive activation of 
Wnt pathway signaling (41). This particular model, Braf/Pten/Ctnnb1, adds the 
activation of Wnt-pathway signaling in the context of Braf activation and Pten 
loss. As demonstrated by previous work in the Bosenberg lab, this triple gene 
combination results in >20 fold increase in lung and lymph node metastases after 
induction, and a 100 to 1000 fold increase in the expression of canonical 
melanoma differentiation antigens relative to the Braf/Pten model (41). 
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Preliminary Data 
 
The Braf/Pten mouse model therefore presents an opportunity to study the Braf 
inhibition in a preclinical animal model. Most BRAFV600E-mutant human 
melanomas respond to vemurafenib (10). The mechanism of either intrinsic or 
acquired resistance in BRAF-mutated melanomas to vemurafenib is variable, but 
includes activation of PDGFR signaling, IGF-1R signaling, or acquisition of 
mutations and other mechanisms that activate MAPK pathway signaling (42, 43). 
Loss of PTEN or increased PI3K activity has been hypothesized to be a 
mechanism of resistance to BRAF inhibitors. This was evaluated in the mouse 
melanomas by determining the dose response in vitro of Braf/Pten melanoma cell 
line—cell lines generated from tumor samples derived from induced mouse 
tumors—to the Braf inhibitor vemurafenib. The IC50s ranged between 200 and 
800nM in three lines, demonstrating that Pten loss does not necessarily mediate 
intrinsic resistance in this system (unpublished data). Furthermore, several 
resistant mouse melanoma lines were generated by chronic in vitro exposure to 
vemurafenib, with IC50 concentrations of >10 µM in resistant clones 
(unpublished data). This supports the hypothesis that the Bosenberg mouse 
Braf-driven melanoma models are responsive to BRAF inhibitors and that 
resistance to BRAF inhibitors which develops has features that resemble those 
seen in human vemurafenib-resistant melanomas; this melanoma mouse model 
represent a useful preclinical system for studying the effects of BRAF inhibitors.  
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In vivo experiments in the Bosenberg lab, in which the Braf inhibitor compound 
PLX4720 was administered in mouse chow, demonstrated that Braf inhibition 
resulted in reduced tumor growth. Overall survival endpoints (primary tumor 
volume >1 cm3 at the site of topical 4OHT induction, or secondary spread), were 
not reached in treated mice in greater than 12 months, verus rapid development 
of induced tumors to endpoint (~2 months) in untreated animal controls. In 
addition, histological evidence of growth arrest (reduced Ki67) and pathway 
inhibition (reduced pMek and pErk) was present in treated tumors following 4 and 
8 days of treatment (unpublished data).  
In addition to testing Braf inhibitors in this model, this system has also been the 
subject of immunomodulatory therapeutic antibody studies. This author’s 
predecessor in the Bosenberg lab, Laura Huang, conducted initial experiments 
on anti-mouse CTLA-4 antibodies as a treatment for induced tumor growth in the 
Bcat/Braf/Pten melanoma mouse model. Her analysis of this treatment showed 
no significant difference between untreated controls (n=12) and those receiving 
the antibody (n=5) in terms of percentage survival as measured to tumor size 
endpoint (44). Subsequently, a pilot study by Laura Huang consisting of a similar 
trial with anti-mouse PD-L1 antibodies on a cohort of mice (n=7) failed to show 
decreased tumor growth (unpublished data).  
 
Thus BRAF inhibition successfully treats mice with induced Braf/Pten/Bcat tumor 
growth, but single agent immune checkpoint blockade failed to stop or slow 
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Braf/Pten/Bcat tumor growth. This later preliminary data presented an 
experimental challenge to determining approaches to therapeutically effective 
immune checkpoint blockade; this observation was explored further in the 
experiments presented herein.  
 
Statement of Purpose 
 
BRAF inhibitors and immune therapies, including anti-CTLA4 and anti-PD1, have 
shown great clinical promise. Additionally, there is encouraging data about the 
ability of TLR agonists, e.g. imiquimod, to promote an effective immune response 
to tumors. Given the encouraging data from new human clinical therapeutic trials, 
there is a clear need to develop approaches that combine these treatment 
strategies. This is an obvious approach and despite a lack of preclinical data, 
human clinical trials of some of these combination therapies are underway, as 
described above (28). These trials will likely determine the efficacy of specific 
individual combination therapies; however, even with biopsy and biomarker 
correlation, the ability to evaluate the mechanism of why the combined therapies 
are effective (or not) is likely to be suboptimal. Prior and ongoing immunotherapy 
trials suggest that partial or complete responses will occur in a subset of patients, 
however to date it has been difficult to prospectively predict which patients will 
respond. In particular, it is difficult to make meaningful conclusions about the 
characteristics of melanomas that respond, as performing sequential biopsies or 
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controlling for tumor or immune genetics are not possible in human patients. 
Understanding the mechanisms of effective combination therapies and rational 
optimization of future therapies will require testing in a pre-clinical animal model 
of BrafV600E-driven melanoma in the setting of an intact immune system. 
 
In order to better understand the mechanisms of action of these combined 
therapies and to better inform future combination therapy clinical trials, I 
measured responses to combined therapies involving PLX4720, anti-CTLA4, 
anti-PDL1, and imiquimod. I hypothesized that effective melanoma treatments 
can be develop using synergistic combination therapies in mouse melanoma 
models. To this end experiments were undertaken using the Braf/Pten/Bcat 
conditional inducible mouse melanoma model to develop combination therapies 
with PLX4720, a tool compound with similar features to vemurafenib, as well as 
immune therapies that include mouse analogues of anti-CTLA4 and/or PD1 
immune checkpoint blockade and/or topical imiquimod. The next step of analysis 
would then be based on the mechanistic insights derived from these mouse 
studies. The purpose of this work was to translate the findings into applications in 
future human clinical trials of combination therapies that result in more frequent 
and more durable responses.  
 
Specific Aims:  
These experiments evaluated the effects of combinations of PLX4720 Braf 
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Inhibitor chow, 5% topical imiquimod, and Anti-CTLA-4/Anti-PD-L1 treatments on 
Bcat/Braf/Pten mouse melanoma’s overall tumor size and survival (as measures 
by an endpoint of 2 cm3). The treated mice were followed for up to a maximum of 
an additional 90 days post treatment. Significant effects on overall survival will be 
determined using Kaplan-Meier survival curves and the log-rank statistic.  
Methods: 
The work herein was completed by Billy Lockhart (BJL) unless otherwise noted. 
 
Animal Model 
The mouse colony was maintained at the Yale University School of Medicine 
Animal Facility and the Yale University Animal Care and Use Committee 
approved all animal protocols. In the facility, the mouse colony was maintained 
under normal parameters, including unrestricted access to fresh water and chow, 
frequent bedding changes, and were checked daily by animal facility staff or by 
this author. Mice were housed in cages in a secured room with the lighting set to 
a 12-hour on/off cycle. 
 
All of the mice in this study were obtained from breeding congenic Tyr::CreER 
Pten flox/flox Bcat sta/sta mice with Braf V600E/V600E Pten flox/flox mice from the 
Bosenberg Lab. All strains were on a congenic C57Bl/6 background. Verification 
of the mouse strain genotypes was completed prior to recombinant breeding and 
induction. The Tyr-CreER, Braf, Pten and BCAT mouse strains were genotyped 
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and assayed for recombination as previously described by the Bosenberg Lab 
(41).  
 
For tumor inductions, 4-hydroxytamoxifen (4-OHT) (#H6278, 70% z-isomer from 
Sigma Aldrich) was dissolved in DMSO to a concentration of 50 mg/ml. For 
localized tumor inductions, a mouse was selected at postnatal day 21 and the 
hair between the shoulder blades was removed with a topical depilatory. Next, 
1µL of 4-OHT at 8.3 mg/ml (dissolved in 1 part DMSO and 5 parts 100 percent 
Ethanol) was directly applied to the skin of the mouse in the hairless area.  
 
Tumor measurement and necropsy methodology: 
The mice were monitored daily for health status and tumor growth. Tumor size 
was captured using a digital caliper measuring three dimensions of the length (L), 
the width (W), and the height (H). The tumors were measured every 7 to 10 days. 
The volume of the tumor was calculated using a formula for the volume of a half 
sphere: 0.523598×L×W×H. If mice developed secondary tumors, the initial tumor 
was designated as the primary tumor and was measured separately from any 
other latent tumor development, which were subsequently labeled by ordinal 
number, i.e. 2nd, 3rd , etc.; in the end only primary tumors were included in 
analysis.  
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Tumor endpoints were establish by animal protocol as tumor volume as 1 cm3 or 
ulcerated tumors, or marked decompensating in animal’s health status (severe 
weight loss, markedly decreased movement, inability to self-care). For these 
experiments, the tumor volume endpoint was approved up to 2 cm3. Mice were 
anesthetized and sacrificed according to Yale University Animal Care and Use 
Committee protocols. Tumors were resected and samples for genetic analysis 
were frozen in -80 C or were stored in formalin and sent for slide preparation in 





Male mice were selected at weaning and rechecked at outset of the treatment. 
The mouse’s treatment cohort was randomly selected, and the experimenter, this 
author, was aware of the treatment group of each cohort and administered all 
drugs. Mice were candidates for inclusion if their primary tumor size was between 
2-6 mm in length or width or 1.5 mm in height, usually ~3 weeks after induction. 
Mouse IgG2b Anti-murine CTLA-4 (clone 9D9) and Rat IgG2b Anti-Mouse PDL-1 
(clone 10F.9G2) were administered via intraperitoneal injection in sterile PBS 
once a week at dosages equivalent to 5 mg/kg according to the mouse’s weight 
at time of administration. The mice that received combination therapy of anti-
CTLA-4 and anti-PD-L-1 (combo) received both intraperitoneal injections on the 
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same day. Both of these antibodies were purchased from BioXCell. The 
Vemurafenib analogue chow, known as PLX4720, was provided to respective 
cohorts as their sole nutrition source (~100mg/kg per day) and was replaced 
weekly; Plexxicon provided the chow to the lab. Imiquimod 5% (generic by 
Fougera) topical cream was administered by small measuring spatula directly to 
the superficial surface of the tumor covering it completely in one layer, 5 days per 
week; the total amount of imiquimod applied was therefore proportional to the 
tumor’s surface area. The mice that received combination therapy of anti-CTLA-4 
and anti-PD-L-1 (combo) received both intraperitoneal injections on the same 
day. Table 1 lists the treatment cohorts. 
Table 1: Treatment Cohorts 
Drug Dosing schedule Dosage (route) 
Anti-CTLA-4 &  
anti-PD-L1 
(combo) 
1x per wk 5mg/kg IP for 
each drug 






1x per wk + chow As above 
Imiquimod 5x week ~25mg (topical) 
Imiquimod plus 
Combo 
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Immunohistochemistry 
IHC was performed on formalin-fixed, paraffin embedded tumor sections. Slides 
were processed using Vectastain ABC –Alkaline Phosphatase kit (Vector, #PK-
5000) and developed with a red alkaline phosphatase substrate kit (Vector, #SK-
5100), according to the manufacturer’s instructions. Responsible investigator: BJL 
with assistance from Katrina Meeth and Goran Micevic. 
 
Antibodies used 
Anti-F4/80 antibody [CI:A3-1] (ab6640) from abcam 
Anti-CD45 antibody (ab10558) from abcam 
 
Statistical Analysis 
Graphpad Prism statistical analysis software was used for all analyses. Kaplan-
Meier survival curves were constructed and significance was determined using 
the log-rank (mantel cox) test.  For comparison of pooled data with two data sets 
unpaired t-test were used. 
 
Results:  
A cohort of 7 untreated male Brafwt/V600E Pten-/- Bcatstab/stab mice from two different 
litters had tumors induced on day 22. The Tumor growth was tracked over four 
months until the tumor sized reached endpoint of 2 cm3. Figure 1 shows the 
measurements of tumor volume over this period of time.  
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Figure 1: Average tumor growth velocity. X-axis represents size of the tumor in millimeters cubed 
and y-axis represents day since birth. 7 untreated male mice with tumors induced on day 22, 
where were recorded over a period of 4 months. Using Excel software, a best fit line was 
calculated for each line and the resulting functions where used to calculate a trend line at precise 
10 day intervals. Each different symbol represents a unique animal’s tumor growth curve. 
 
The chart shows the range of tumor size at various time points, and the trend line 
provides a rough approximation of when the average tumor size at various points 
in time. By this calculation, the trend line shows that a given tumor’s volume 
would most likely reach 1 cm3 in approximately 76 days post-induction, and the 
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same tumor would reach 2cm3 volume in 90 days. The fastest growing tumors in 




Figure 2: Kaplan-Meier analysis of Brafwt/V600E Pten-/- Bcatstab/stab mice that received Plx4720 chow 
(n=6) and those mice that received no treatment (n=7) starting 3 weeks post induction (day 45) of 
melanomas. 
 
The 6 animals treated with the PLX4720 received their treatment continuously, as 
past experience indicated that after stopping the chow tumor growth would re-
start. The survival curve in figure 2 shows the difference in survival past 100 
days. For animals not receiving treatment medial length of survival was ~100 
days. PLX4720 treated cohort did not reach median survival point. There is a 
significant difference in time to endpoint when the Brafwt/V600E Pten-/- Bcatstab/stab 
mice received Braf inhibitor therapy versus controls (p=0.0051). 
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Figure 3: Kaplan-Meier analysis comparing percent survival of Brafwt/V600E Pten-/- Bcatstab/stab mice 
treated with the Braf inhibitor Plx4720 chow (n=6), the treatment arm receiving weekly combined 
Anti-CTLA-4/Anti-PD-L1 treatment (n=6), and those with no treatment (n=7) starting 3 weeks post 
induction (day 45) of melanomas. 
 
The treatment arm (n=6) receiving combination immune checkpoint point 
blockade antibodies, anti-CTLA-4 and anti-PD-L1, did not vary significantly from 
controls in terms of time to endpoint, i.e. survival (p=0.77). Figure 3 compares 
both the survival percentage of the combination checkpoint blockade group and 
Braf inhibitor group (plx4720) to untreated controls with induced tumors. 
Additionally, a cohort of mice (n=4) received the two checkpoint blockade 
antibodies in addition to chow with PLX4720 (Figure 4). The percent survival of 
this cohort differed significantly from the untreated group (p=0.42), but this 
difference is attenuated when comparing this treatment group to the mice that 
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received the PLX4720 Braf inhibitor chow only (Figure 5); when compared to Braf 




Figure 4: Kaplan-Meier analysis comparing percent survival of Brafwt/V600E Pten-/- Bcatstab/stab mice 
treated with the Braf inhibitor Plx4720 chow in addition to Anti-CTLA-4 and Anti-PD-L1 (n=4), and 
those with no treatment (n=7) starting 3 weeks post induction (day 45) of melanomas. 
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Figure 5: Kaplan-Meier analysis comparing percent survival of Brafwt/V600E Pten-/- Bcatstab/stab mice 
treated with the Braf inhibitor Plx4720 chow in addition to Anti-CTLA-4 and Anti-PD-L1 (n=4), as 
compared to the percent survival of the group treated only with Plx4720 (n=6) starting 3 weeks 
post induction (day 45) of melanomas. 
 
 
Figure 6: Unpaired t-test analysis comparing mean tumor volume (mm3) per treatment cohort at 
approximate day 60 (5.4 weeks of treatment) and day 120 (14 wks of treatment). 
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A                  B 
 
Figure 7. A) An unpaired comparison analysis of the individual tumor volumes (mm3) in the 
plx4720 only versus plx4720 plus combination immune checkpoint blockade antibodies at d60, 
~38 days post induction. Panel B shows the same analysis done with tumor volumes at d120, 
~98 days post induction. 
 
 
Figure 6 depicts results of statistical comparison between the mean tumor size at 
early and late time points for each treatment arm (PLX4720 alone, with Anti-
CTLA-4/Anti-PD-L1, and controls). The difference in tumor size when comparing 
the two treatment arms was not significant at either time point. Figure 7A and 7B 
shows a similar analysis with the spread of tumors sizes for the two treatment 
arms at the respective time points.  
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Figure 9: Brafwt/V600E Pten-/- Bcatstab/stab mice (n=6) were treated with 5% topical imiquimod and 
their mean tumor volumes (mm3) were compared 45 days post induction to a group of control 
mice (n=6) with untreated tumors. This experiment was completed by Katrina Meeth 
 
Imiquimod demonstrated a significant effect on the inhibition of tumor volume 
(mm3) in mice (n=6) after 4 weeks of treatment when compared to untreated 
control mice with induced melanomas (n=6) (Figure 9). When imiquimod was 
applied to tumors and the treated mice were administered the combination anti-
CTLA4/anti-PDLI (Figure 10, 11), the treatment was highly effective in retarding 
tumor growth. 
      11 
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Figure 10: Brafwt/V600E Pten-/- Bcatstab/stab mice (n=5) were treated with 5% topical imiquimod and 
combination Anti-CTLA-4/Anti-PD-L1 and their mean tumor volumes (mm3) were compared to a 
group of control mice (n=6) with untreated tumors at day 77. Figure 11: the same imiquimod 
treatment cohort compared to a plx4720 cohort (n=6) at day 60. 
 
Untreated F4/80 staining       Imiquimod tx’d F4/80 stained 
	   	    
Untreated CD45 staining       Imiquimod tx’d CD45 stained 
	   	    
Figure 12: Immunohistochemical staining of tumor samples taken from untreated Brafwt/V600E Pten-
/- Bcatstab/stab mouse tumors compared to imiquimod treated tumors. The top row shows staining 
for F4/80 and the bottom row show staining for CD45. 
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Samples from imiquimod treated tumors were embedded and sectioned for 
histology. Immunohistochemical assays demonstrated that treated tumors had a 
increased F4/80 staining increased CD45 staining (Figure 12 Additional results 
from preliminary, but not fully validate, immunohistochemistry suggest that CD3 




This worked examined various combinations of cancer drugs in a preclinical 
mouse model. The mouse model offers many advantages; particularly as it has 
been genetically engineered to share driver mutations identical to human 
melanomas and the mouse maintain their native, intact immune system. In these 
therapeutic trails, the primary endpoints were directly measured, and only this 
author measured the tumor dimensions to avoid inter-operator variability.  
 
During the initial pilot phases of these experiments, a measurement optimization 
was undertaken by using triplicate measurements by the same observer 
averaging the values to ensure best possible accuracy and to established rough 
parameters for measurement error (estimated at +/- 1mm for any given 
dimension measurement). The spread of the tumors sizes for given time points 
are quite large, and their growth curve velocity can differ significantly. This large 
spread has implications on the detection of difference in tumor response (Figure 
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1).	  Previous experimenters working on the same model assessed tumor 
dimensions bi-weekly. However, considering the initially slower pace of tumor 
growth after induction (Figure 1), bi-weekly measurements were deemed to 
easily fall within the +/- 1mm error range, and as such the tumors measurements 
were spaced out to every 7 to 10 days for these trials in order to better capture 
actual changes in tumor size. Furthermore, variability in the growth 
characteristics of a given tumor, including growth rate and shape, and this lack of 
uniformity in tumor physical characteristics were in part due to the difficulty in 
administering the 4-hydroxy-tamoxifen due to uneven spread of the liquid over 
the non-flat surface of the animal’s hind quarters and the rapid evaporation rate. 
Previous experiments in the lab established that less spread produced a smaller 
initial induction area and a tumor with decreased growth velocity when compared 
to larger spread/larger induction areas (44). Initial attempts to optimize this 
induction procedure were tried, including injection of induction material 
intradermal as well as subcutaneously, but the piloted results were not 
adequately consistent. Larger sample sizes may have improved the statistical 
comparisons and in future iterations of these trials in this system; these 
observation supports using more animals per treatment arm. 
 
Another possible explanation for growth velocity variation may have to do with 
uncharacterized genetic factors. Note that un-induced mice have a 20-25% 
chance of developing spontaneous melanomas within 6 months in the absence of 
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4-OHT induction, an observation attributed to “leaky” Cre expression. In this 
author’s experience, these spontaneous tumors are unpigmented, uninodular, 
and dermal and can appear at any surface point of the affected mouse. Once 
they appear, these tumors grow quite rapidly.  
 
Experimental data at present suggests that anti-CTLA-4 therapy is not better than 
control in the Braf/Pten/Bcat mouse model. Similarly, neither single agent anti-
PD-L1, nor the combination of the two antibodies appears to effect survival 
significantly versus controls (figure 3). The results of the trial testing BRAF 
inhibition in combination with anti-CTLA-4/anti-PD-L1 have not yielded significant 
results to date (figure 5). This begs the interesting question: why? Are the mouse 
analogues of the human antibodies not as effective at inhibiting their target? Mice 
lacking CTLA-4 die at an age of 2–3 weeks secondary to massive 
lymphoproliferation (45), clearly the protein plays a significant role in down-
regulating the immune system in mice. In 1995, Kearney et al showed that 
blocking CTLA-4 in mice greatly enhanced antigen specific clonal expansion, but 
those experiments used a specially engineered antibody in a Fab form “as 
described by Wassau” (46). Severe immune side effects in human patients on 
anti-CTLA-4 therapy have been documented (22), yet no severe side effects 
where noted in these trials (5mg) or in previous trials in the labs at twice the dose 
(10mg/kg the highest dose given) in humans during phase II trials. Furthermore 
animals were dosed weekly as opposed to every third week. A future experiment 
designed such that multiple mouse anti-CTLA-4 sourced from different 
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manufacturers is administered in increasing doses until side effects are observed 
may help characterize how the mouse immune system responds to the anti-body. 
Or perhaps the Wassau method should be resumed for anti-CTLA-4 antibody 
production.  
 
Another compelling difference between the mouse model and human melanomas 
is how few mutations they posses – melanomas are know to contain a relatively 
high numbers of mutations and also to be relatively antigenic (2). The three 
induced mutations in the model suffice for melanoma growth but may be sub-
threshold to activate the immune system’s surveillance. It’s worth noting that that 
when immune checkpoint inhibitors are administered to humans in clinical trails a 
substantial fraction have no response, as high as ~85%.  
 
It is possible that specific genetic drivers of melanoma and other cancers can be 
associated with induction of an immunosuppressive tumor microenvironment. In 
unpublished work from the Gajewski lab at the University of Chicago, it appears 
that the Braf/Pten/Cnntb1 model induces potent local tumor microenvironment 
immunosuppression compared to the Braf/Pten model. These findings may 
indicate the reason for the relative lack of effect of the combined anti-CTLA-4 and 
anti-PD-L1 therapy in the Braf/Pten/Cnntb1 model. 
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As had been supported by prior experiments, results from treatment cohorts of 
mice receiving the Braf inhibitor chow, PLX4720, demonstrated that the drug 
effectively inhibits tumor growth for the life of the animal as long as the treatment 
is continued. Adding Anti-CTLA-4 and Anti-PD-L1 offered no significant benefit in 
efficacy (figure 5). A human trial that combined vemurafenib and ipilimumab was 
stopped due to toxicity when the drugs were used in combination (47), an effect 
not noted in the combination trial in the mouse model. A recent collaboration 
between the Bosenberg and Kaech laboratories established that T-cells are 
involved in the Braf-inhibitors mechanism of growth suppression (48). However, 
based on preliminary analysis of mouse melanoma responses to PLX4720, 
induction of apoptotic cell death is minimal. Therefore it is possible, that PLX4720 
treatment alone may be insufficient to generate effective immune responses in 
combination with anti-CTLA4 and/or PD1 pathway inhibition.  
 
Another difference between these trials and the standard of care in humans is 
surgical excision. Humans usually present with a primary melanoma on the skin, 
which is subsequently almost always surgically removed; the administration of 
systemic agents is reserved for metastatic disease. Does post-surgical excision 
wound healing alter the tumor microenvironment in ways fundamental to 
generating a more effective T-cell response to melanoma cells? Is cell death a 
prerequisite to step to activating a T-cell response that can be further enhanced 
by immune checkpoint blocking antibodies? Laura Huang, this author’s 
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predecessor in the Bosenberg lab, has performed experiments administering a 
brief pulse of treatment with a cytotoxic agent (temozolomide) before initiation of 
immune therapies in established tumors results in minor improvements in survival 
of treated mice, but her data show the median end points are identical between 
chemotherapy alone or with anti-CTLA-4 therapy(44). Several pilot experiments 
in which tumor bearing mice receiving treatment has tumors directly injected with 
cytotoxic agents or inoculation with cultured melanoma cell lines that had been 
lysed did not result in encouraging results (unpublished data). 
 
Treatment with 5% topical Imiquimod significantly retards tumor growth and 
thereby increases time to end point in this model (figures 10,11). Imiquimod 
causes visible inflammation at application site, massive splenomegaly, and 
weight loss when applied at high doses in this mouse model, according to 
previous work by Katrina Meeth. At the doses used in these experiments, no 
such side effects were noted. Perhaps higher doses of imiquimod combined with 
immune checkpoint blocking agents would provide the impetus for an effective 
immune response. Immune cell infiltrate characterization of treated tumor 
samples reveals increased macrophage subsets. Preliminary FACS analysis of 
imiquimod treated samples does not yet show a consistent pattern of increased T 
cell populations. RNA Seq Gene expression analysis could yield interesting leads 
to follow up in future experiments that would in form ongoing and future human 
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clinical trials involving these agents and are likely to be critical to the success of 
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